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Abstract 
AIM: Describe the efficacy and safety of valproate and haloperidol infusion in controlling agitation in the intensive 
care unit (ICU). 
MATERIAL AND METHODS: Prospective study on 100 critically ill patients with agitation in Kasralainy Hospital 
over the period from May 2016 to June 2017.patients were divided into two groups, each group included 50 
patients, 1st group patients received Depakene orally, and 2nd group patients received haloperidol by i.v infusion 
for 72 h. Richmond agitation sedation score and doses of additional sedative drugs were noted and calculated 
daily in the first three days. 
RESULTS: Our study showed that valproate was equal in efficacy in controlling agitation; decreasing the RAAS 
significantly after 48 h from initiation (2.52 ± 0.61 vs 0.28 ± 0.54 with p < 0.001) for Depakene and (2.6 ± 0.67 vs 
0.34 ± 0.48 with p < 0.001) for haloperidol. There was also a decrease in the doses of additional sedative drugs 
used to control agitation (midazolam & propofol) after 48 h from drug initiation. Both drugs therapy was associated 
with decrease in heart rate (89 ± 20 vs 86.6 ± 13.6 with p = 0.002 for valproate and 99.8 ± 23.3 vs 91 ± 16.7 with 
p < 0.001 for haloperidol). They did not affect blood pressure. Haloperidol therapy was associated with significant 
QTc prolongation. 
CONCLUSION: Valproate was equal in efficacy as haloperidol infusion in controlling agitation in ICU and 
decreasing the doses of additional sedative drugs used after 48 h from initiation. 
 
 
 
Introduction 
 
Agitation occurs in up to 70% of critically ill 
patients and is a significant source of distress for 
patients, families, and providers (Fraser GL et al., 
2000). Sedatives are administered to 50% of intensive 
care unit (ICU) patients to alleviate agitation [1]. 
Choice of sedative is complex and largely driven by 
patient context. No sedative has consistently been 
shown to be superior to the rest, and alternative 
agents are greatly needed [2]. Most ICU patients, 
especially those requiring mechanical ventilation, are 
treated with opioids, propofol, and/or benzodiazepines 
[1], [3]. Use of these agents is limited by adverse 
effects (e.g., hemodynamic derangement) for safe 
administration [4]. New therapies for treating agitation 
are rarely introduced into practice, with 
dexmedetomidine being the most recent in 1999. 
Consequently, providers have increasingly 
repurposed older pharmacologic agents as ICU 
sedatives (e.g., clonidine, Phenobarbital, and 
valproate (Depakene) [5], [6]. 
Haloperidol is a butyrophenone that works by 
blocking D2 receptors, probably in the mesolimbic 
region [7]. Its side effects include extrapyramidal 
symptoms, and rarely, the neuroleptic malignant 
syndrome [8]. The patient should be monitored for 
precipitation of arrhythmias such as torsade de points 
[9] and haloperidol should be used with caution in 
patients with a QTc interval of over 450 msec. 
National guidelines for the management of 
agitation/delirium recommend short term haloperidol if 
non-pharmacological measures are not effective. 
Depakene is an antiepileptic and mood 
stabiliser approved for the treatment of seizures, 
manic episodes associated with bipolar disorder, and 
migraine prophylaxis. Mechanistically, it blocks 
voltage-dependent sodium and calcium channels, 
increases γ-aminobutyric acid (GABA) synthesis, 
potentiates GABA activity at postsynaptic receptors, 
blocks GABA degradation, and attenuates the activity 
of glutamate upon N-methyl-D-Aspartate receptors 
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[10], [11]. 
 Recently, valproate has been administered to 
critically ill patients to treat agitation and delirium, but 
there are few published reports to support this 
practice [12], [13], [14]. Valproate is an emerging 
treatment for ICU agitation because it allows patients 
to interact with their caregivers; can be administered 
outside of the ICU; has both an intravenous (IV) and 
enteral formulation; has a low drug acquisition cost; 
and has not been associated with respiratory 
depression, hemodynamic derangements, or delirium. 
In this study, we describe the use of Depakene & 
haloperidol for agitation in critically ill patients and 
examine their safety.
 
We aimed to evaluate the adding effect of a 
calcium sensitiser (levosimendan) compared to the 
conventional inotropic and vasoactive agent used in 
the patient with poor left ventricular function 
undergoing cardiac surgery on different measured 
hemodynamic variables and the effect on the 
outcome. 
 
 
Material and Methods 
 
Study design 
Our study was a prospective one on Agitated 
critically ill patients in kasralainy hospital, critical care 
department over the period from May 2016 to June 
2017. Patients included if they were above 18 years 
old and has severe agitation (score ≥ 2 on RAAS) 
patients were excluded if they have advanced cardiac 
diseases, hepatic diseases, advanced malignancy or 
if they were on antiepileptic. Our study was conducted 
on 100 patients divided in two groups; each group 
included 50 patients. Patients in group I received 
Depakene orally, and patients in group II received 
haloperidol by i.v. Infusion for 72 h. 
 
Demographic data and patients'  
   characteristics 
Patient demographic data included age, sex, 
weight, history of psychiatric diagnosis, alcohol or 
substance abuse, the reason for ICU admission, need 
for mechanical ventilation. Clinical outcomes were 
descriptive and included ICU length of stay and ICU 
mortality. 
 
Efficacy outcomes 
Efficacy data were collected from day of drug 
(valproate or haloperidol) initiation and continuing for 
72 h or until discontinuation, whichever came first. 
The 3-day interval was selected to allow a reasonable 
time to observe efficacy or lack thereof, the agitated 
patients were examined daily and Richmond 
Agitation-Sedation Scale (RASS) was assessed daily 
from drug initiation up to 3days. Also, the doses of 
additional sedative drugs were noted and documented 
daily during drug therapy. 
 
Safety outcomes 
Safety parameters were examined for the 
hospital duration of valproate and haloperidol therapy. 
Records were specifically reviewed for possible 
hepatotoxicity, hematologic toxicity for both drugs and 
QTc prolongation for haloperidol. The number of 
patients who had discontinued because of a 
suspected adverse event was also recorded. 
Hepatotoxicity was defined as a new alanine 
aminotransferase 3 times the upper limit of normal 
(120 U/L), alkaline phosphatase 2 times the ULN (234 
U/L), total bilirubin 2 times the ULN (2 mg/dL), or a 
doubling of the baseline value if it was already 
abnormal following drug initiation. Suspected cases of 
hepatotoxicity were further assessed using the 
validated Roussel Uclaf Causality Assessment 
Method (RUCAM) [15]. Hematologic toxicity was 
defined as a new leukocyte count 4200 cells/mm3, 
absolute neutrophil count 2400 cells/mm3, or platelet 
count 140 000 cells/mm3 or platelet drop by 50% if 
platelets were already 140 000 cells/mm3 following 
valproate initiation. 
 
 
Results 
 
Demographic data and patient 
 characteristics 
One hundred patients were included in the 
study. The mean age of the studied population was 
63.7 ± 15 years; the youngest was 22 years; they 
included 54 Males and 46 Females. Regarding 
Comorbidities; in our study 36 Smokers, 42 with pre-
existing Cardiac patients (Ischemic heart disease and 
chronic heart failure) and 39 with pre-existing Renal 
patients (serum creatinine ≥ 1.4 mg/dl). End organ 
failure (45%), sepsis (40%) and Stroke (hemorrhagic 
and non-hemorrhagic) (15%) were the most common 
reasons for ICU admissions. The mean length of ICU 
stay was 7 days, 21 patients died in the ICU. 
Table 1: Baseline characteristic data of the total population 
Age (mean ± SD) years 63 ± 15 
Gender-females n 46 
Weight (mean ± SD) kg 76.5 ± 14 
Smokers n (%) 36 
Pre exciting Cardiac disease n (%) 42 
Pre exciting Renal disease n (%) 39 
ICU Mortality (%) 21% 
ICU stay (mean) days 7 
Causes of admission 
End Organ failure (%) 
Sepsis (%) 
Stroke (%) 
 
45% 
40% 
15% 
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Efficacy outcomes 
Regarding valproate group; the severity of 
agitation decreased after 48 h from starting valproate 
therapy; RASS score decrease from 2.52 ± 0.61 to 
0.28 ± 0.54 before and after depakene initiation 
respectively with P value < 0.001. The doses of 
concomitant sedative drugs used to control agitation 
(midazolam & propofol) decreased after 48h from drug 
initiation (77.2 ± 82.4 mg/day vs. 0 mg/day) and (3.5 ± 
2.0 gm/day   vs.  0.35 ± 0.49 gm/day) with P value 
0.004 and 0.135 respectively. Regarding haloperidol 
group; the severity of agitation decreased after 48 h 
from starting valproate therapy; RASS score decrease 
from 2.6 ± 0.67 Vs 0.34 ± 0.48 before and after 
depakene initiation respectively with P value < 0.001. 
The doses of concomitant sedative drugs used to 
control agitation (midazolam & propofol) decreased 
after 48 h from drug initiation (101 ± 141 mg/day vs. 
16 ± 33 mg/day) and (1.6 ± 1.9 gm/day   vs.  0.33 ± 
0.7 gm/day) with P value < 0.001. 
 
Hemodynamic response 
The Depakene group showed a statistically 
significant difference regarding HR after 48 h from 
valproate therapy (89 ± 20 vs 86.6 ± 13.6) with P-
value 0.002, there was no effect on systolic or 
diastolic blood pressure. Haloperidol group showed a 
statistically significant difference regarding HR after 
48 h from haloperidol (99.8 ± 23.3 vs 91 ± 16.7) with 
P-value < 0.001, there was no effect on systolic or 
diastolic blood pressure. 
Table 2: Efficacy outcomes and hemodynamic response for 
both groups 
 Depakene group Haloperidol group 
 Day 0 Day 2 Day 0 Day 2 
RASS 2.52 ± 0.61 0.28 ± 0.54 2.6 ± 0.67 0.34 ± 0.48 
Midazolam 0.77 ± 0.82 0 101 ± 141 16 ± 33 
Propofol 3.5 ± 2.0 0.35 ± 0.49 1.6 ± 1.2 0.33 ± 0.7 
Heart rate 89 ± 20 86 ± 13 99.8 ± 23 91 ± 16.7 
Systolic BP 125 ± 18.8 121.8 ± 10 124.8 ± 17.7 122.6 ± 11.7 
Diastolic BP 79.4 ± 8.6 78 ± 5.6 80.6 ± 6 80.4 ± 5 
 
Safety outcomes 
All patients had complete blood picture & liver 
function tests monitored during drug therapy, In 
valproate group; Hemoglobin level and Total 
leucocytic count showed significant decrease after 48 
h from valproate therapy with p = 0.002 & 0.025 
respectively. Liver enzymes (ALT & AST) showed a 
significant increase after 48 h from valproate therapy 
with p < 0.0001. One patient developed hepatotoxicity 
(elevation of ALT ≥ 120 IU/ml) but was unrelated to 
the drug as his RUCAM score was 1. Regarding 
haloperidol group; Hemoglobin level & Total leucocytic 
count showed significant decrease after 48 h from 
haloperidol therapy with p = 0.004 & < 0.001 
respectively. Liver enzymes (ALT & AST) showed no 
significant differences after 48 h from haloperidol 
therapy. One patient developed hepatotoxicity 
(elevation of ALT ≥ 120 IU/ml) but was unrelated to 
the drug as his RUCAM score was 3. There was 
significant QTc prolongation after 48 h from 
haloperidol initiation with p < 0.001, but this was not 
associated with major cardiac events (VT or VF). 
Table 3: Safety outcomes and hemodynamic response for both 
groups 
                                                               Depakene group Haloperidol group 
Lab Day 0 Day 2 Day 0 Day 2 
Hemoglobin gm/dl 10.6 ± 1.9 10.2 ± 1.5 10.6 ± 1.9 10 ± 1.7 
Total leucocytic count cells x 10
3
 10.7 ± 9 9.2 ± 7 13 ± 8 10 ± 5 
Platelets cells x 10
3
 253 ± 103 245 ± 102 209 ± 88 212 ± 94 
ALT IU/ml 44 ± 32 49 ± 100 49 ± 83 39 ± 36 
AST IU/ml 39 ± 25 48 ± 126 47 ± 66 39 ± 33 
Bilirubin IU/ml 0.62 ± 0.5 0.58 ± 0.47 1.32 ± 2.5 1.2 ± 2.3 
 
 
 
Discussion 
 
Regarding efficacy outcomes in Depakene & 
haloperidol groups of our study, there was a 
significant decrease in the severity of agitation after 
48 h from drug initiation with Richmond agitation 
sedation scores p < 0.001. Also, there was a marked 
decrease in the doses of concomitant sedative drugs 
used to control agitation (Midazolam & propofol) after 
48 h from drug initiation. Similarly, Gagnon et al., 
(2017) performed a retrospective cohort study 
evaluated critically ill adults treated with Depakene for 
agitation on Fifty-three patients and showed that the 
incidence of agitation significantly decreased following 
the initiation of Depakene from 96% to 61% on 
Depakene day 3 (P < 0.001). Also, in this study, 
Depakene therapy was associated with reduced 
doses of concomitant sedative drugs [16]. Riker et al. 
(1994) evaluated the Continuous infusion of 
haloperidol in critically ill agitated patients. This study 
was performed on eight patients required mechanical 
ventilation who had severe agitation which was 
refractory to intermittent bolus treatment with 
benzodiazepines, narcotics, and haloperidol. These 
patients received Continuous infusion of haloperidol to 
maintain adequate sedation. This study showed that 
there was a significant decrease in the Sedation-
Agitation Scale after 48 h from haloperidol initiation 
(+2.4 vs +0.8) and (P = 0.06). Also, there was a 
marked reduction in the daily total of non-haloperidol 
sedatives after 48h of continuous infusion of 
haloperidol with (P-value = 0.15) [17]. 
Regarding Hemodynamics response after 
Depakene & haloperidol initiation, our study showed 
that there was significant decrease in patients heart 
rate after 48 h from drug initiation with p = 0.002 & < 
0.001 respectively, blood pressure showed no 
significant changes before and after drug initiation. 
Sinha et al., (2000) reviewed hospital records of 13 
patients with status epileptics and hypotension who 
received IV Depakene therapy. There were no 
significant changes in blood pressure, pulse, or use of 
vasopressors. The data suggest that Depakene 
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loading is well tolerated, even in patients with 
cardiovascular instability [18], also Riker, et al., (1994) 
evaluated the Continuous infusion of haloperidol in 
eight critically ill agitated patients. There were no 
hypotension episodes noted [17]. 
Regarding safety outcomes, our study 
showed that hepatotoxicity (ALT ≥ 120 IU/ml) had 
developed for one patient (2%) hepatotoxicity is 
unlikely to be related to the drug (Depakene or 
haloperidol) as RUCAM score was 1 and 3 
respectively which make hepatotoxicity is unlikely 
related haloperidol [15]. Possible reasons for 
hepatotoxicity in these patients are the underlying 
disease. 
QTc prolongation for all patients in the 
haloperidol group with one patient had significant QTc 
prolongation ≥ 500msec after 48 h from haloperidol 
therapy, but this QTc prolongation was not associated 
with major cardiac events. That agrees with Tisdale et 
al., who assessed the effect of intravenous haloperidol 
on QT interval dispersion in critically ill patients who 
received intravenous haloperidol for delusional 
agitation. QTc intervals were measured, and QT 
interval dispersion was calculated.  
Haloperidol prolonged QTc interval compared 
to pretreatment values in Torsades de Pointes 
patients by a greater magnitude than in patients who 
did not experience Torsades de Pointes. It was 
concluded that intravenous haloperidol prolongs QTc 
intervals in critically ill patients [19]. 
Also, there was a significant decrease in 
Hemoglobin levels and total leucocytic count after 48 
h from haloperidol therapy. Possible reasons for that 
decrease of the total leucocytic count are that TLC 
was elevated on day 0 of drug initiation due to sepsis 
which decreased with starting broad-spectrum 
antibiotics & control of sepsis. Also, the possible 
reasons for decreased level of hemoglobin are 
dilutional effect of intravenous fluids, blood sampling 
for lab and bone marrow suppression from sepsis. 
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